The Effects of Nanoplastics on the Dopamine System of Cerebrocortical Neurons

Abstract

Nanoplastics (NPx) can enter living organisms, including humans, through ecosystems, inhalation, and dermal contact and can be found from the intestine to the brain. However, it is unclear whether NPx accumulates and affects the dopamine system. In this study, we investigated the effects of NPx on the dopamine system in cultured murine cerebral cortex neurons. Cultured cerebrocortical neurons were treated with 100 nm NPx at the following concentrations for 24 h: 1.896 × 10⁵, 3.791 × 10⁶, 7.583 × 10⁷, 1.571 × 10⁹, 3.033 × 10¹⁰, and 3.033 × 10¹¹ particles/mL. Dopamine-associated proteins were analyzed using immunofluorescence staining. NPx treatment induced its accumulation in neurons in a dose-dependent manner and increased the levels of dopamine receptors D1 and D2 and their co-expression. However, NPx treatment did not affect the levels of other dopamine receptors, dopamine transporters, tyrosine hydroxylase, and microtubule-associated protein 2, or synaptophysin in neuronal structures. This study demonstrated that NPx is a potential modulator of the dopamine system via its receptors rather than its synthesis and reuptake in neurons and may be associated with dopamine-based psychiatric disorders.

Keywords

nanoplastics dopamine dopamine receptor D1 dopamine receptor D2 neural function

Introduction

Industrial development contributes to the convenience of human life but causes the overproduction of environmental pollutants. Among many pollutants, nanoplastics (NPx) are degraded microplastics and are released from sources such as electronics and commercial products.¹ NPx are defined as plastic particles less than 1 μm. In contrast, microplastics refer to plastic particles between 1 μm and 1000 μm.² Notably, since the size of NPx is similar to that of a virus, they can easily penetrate biological membranes. Therefore, living organisms are more susceptible to these than to microplastics.^2,3

NPx can enter living organisms, including humans, through ecosystems, inhalation, and dermal contact.⁴ In the case of humans, NPx are found in the intestine, liver, lungs, and kidney.¹ In in vivo and in vitro systems, NPx can cross the placenta and blood–brain barrier,^5,6 indicating that NPx accumulate in the fetus as well as in the brain. The absorption of NPx from the external environment into living tissues and the permeabilization of NPx through organic membranes in living organisms causes various health-associated problems in the immune, respiratory, digestive, cardiovascular, and endocrine systems.⁷ Moreover, NPx may lead to various neurological diseases by inhibiting acetylcholine esterase, impairing autophagy, and causing deficits in cognitive function and abnormal behaviors.⁸ However, the effects of NPx on specific neurological pathways, such as the dopamine (DA) system, remain unclear.

DA is a major neurotransmitter that originates from the ventral tegmental area and the substantia nigra, which is compact and innervates the prefrontal cortex, striatum, and amygdala.^9,10 Tyrosine hydroxylase synthesizes DA from tyrosine; calcium influx subsequently activates the vesicular monoamine transporter (VMAT)-2 to release DA into the extracellular space. Extracellular DA can then either undergo reuptake by the DA transporter (DAT) on presynaptic nerve terminals or bind to 5 types of DA receptors, characterized as D1R, D2R, D3R, D4R, and D5R.^10,11 DA receptor binding specifically affects synaptic plasticity via various signal cascades, and all these processes are considered part of the DA system. Alterations in the DA system have been implicated in several psychiatric disorders, including schizophrenia, attention deficit hyperactivity disorder, and Parkinson’s disease.^12-14 The accumulation of pollutants in living organisms affects brain functions associated with the DA system. The influx of perfluoroalkyl substances as pollutants decreased the DA content and tyrosine hydroxylase expression in the brain,¹⁵ whereas lead exposure increased tyrosine hydroxylase and DAT levels in the brain.¹⁶ Particulate matter exposure accelerated dopaminergic neuron death in a Parkinson’s disease cellular model.¹⁷ However, the effects of NPx on the DA system have rarely been reported. In zebrafish, neither bisphenol A nor 50 nm NPx caused any changes in DA levels, although their combination induced an increase in DA levels in the head of zebrafish.¹⁸ Using SH-SY5Y cells as representative dopaminergic neurons, 50 nm NPx led to cell death by activating mitophagy through the adenosine monophosphate-activated protein kinase (AMPK)/Unc-51 like autophagy activating kinase 1 (ULK1) pathway.¹⁹ This indicates that NPx, similar to other pollutants, can diffuse into the brain and affect the DA system. However, the exact mechanism through which NPx affect the DA system is unclear; therefore, in this study, we investigated the effects of NPx on the DA system in vitro using cerebrocortical neurons.

Materials and Methods

Primary Cell Culture

Animal experiments were conducted in accordance with the Institutional Animal Care and Use Committee of Daegu Catholic University (IACUC-2023-030). Institute of Cancer Research (ICR) mice, an outbred strain, were chosen for primary cell culture because they have a similar genetic background to humans, which can simulate the genetic diversity found in humans.²⁰ Cerebrocortical neurons from ICR mice were cultured on embryonic day 14 (Youngnam-Bio, Inc, Daegu, Korea). After pregnant ICR mice were anesthetized, embryos were separated from the dams, their brains were removed from the skull, and cerebrocortical neurons were dissected. Eight-well chamber slides were coated with 5.0 μg/mL poly-D-lysine (catalog #P6407, Sigma-Aldrich, St. Louis, MD, USA) for 24 h prior to cell harvesting. Cerebrocortical neurons were cultured at 1.5 × 10⁵ cells/well on these coated slides in a neurobasal medium (catalog # 21103049, Gibco, Rockville, MD, USA) supplemented with 12% horse serum (catalog # 26050070, Gibco), 0.6% glucose, and 2 mM L-glutamine, in an incubator controlled at 37°C with 5% CO₂. One day after incubation, the medium was replaced with a fresh neurobasal medium supplemented with 2% B-27 (catalog # 17504044, Gibco). After 4 days of cultivation, the cells were treated with 100 nm NPx (Catalog # 64010-15, Polysciences, Warrington, PA, USA) at the following concentrations: 1.896 × 10⁵, 3.791 × 10⁶, 7.583 × 10⁷, 1.571 × 10⁹, 3.033 × 10¹⁰, and 3.033 × 10¹¹ particles/mL. The same doses were used for 100 nm fluorescent-NPx (Catalog # PS100-FC-1, Nanocs, New York City, NY, USA). As a control, the vehicle (VEH) was treated with distilled water at the same volume as the NPx solution. After 24 h, all cells were treated with 4% paraformaldehyde for 2 h, and immunostaining was performed.

Fluorescence Immunostaining

The mouse monoclonal anti-tyrosine hydroxylase (TH; catalog # ab129991, Abcam, Cambridge, UK), rabbit polyclonal anti-DA transporter (DAT; catalog # sc-14002, Santa Cruz, Dallas, TX, USA), rabbit polyclonal anti-DA (catalog # ab6427, Abcam), rabbit polyclonal anti-D1R (catalog # sc-14001, Santa Cruz), mouse monoclonal anti-D2R (catalog # sc-5303, Santa Cruz), mouse monoclonal anti-D3R (catalog # sc-136170, Santa Cruz), rabbit polyclonal anti-D4R (catalog # ab20424, Abcam), rabbit polyclonal anti-D5R (catalog # MBS2516950, Mybiosource, San Diego, CA, USA), mouse monoclonal anti-synaptophysin (SYP, catalog #s5768, Abcam), rabbit polyclonal anti-SYP (catalog # PA1-1043, Invitrogen, Carlsbad, CA, USA), mouse monoclonal anti-microtubule-associated protein 2 (MAP2; sc-32791, Santa Cruz), and rabbit polyclonal anti-MAP2 (AB5622, Merck Millipore, Burlington, MA, USA) were used as primary antibody. Twenty-four hours after NPx treatments, the cells were fixed with 4% paraformaldehyde for 2 h and washed three times with phosphate buffer saline (PBS). The cells were subsequently incubated with primary antibodies for 24 h at 4°C. After treatment, secondary Alexa Fluor 488 goat anti-mouse IgG antibody (catalog # A-11001, Life Technologies, Waltham, MA, US) and Alexa Fluor 594 goat anti-rabbit antibody (catalog # A-11012, Life Technologies) were added for a 2 h incubation at room temperature. For nuclei visualization, 4′,6-diamidino-2-phenylindole (DAPI; catalog # 10236276001, Roche, Basel, Switzerland) was added for a 10 min incubation. After washing thrice with PBS, the immunostained cells were mounted with an aqua-poly mount (catalog # 18606, Polysciences, Warrington, PA, USA). Images of stained cells were captured using a fluorescence microscope (Leica DM2500, Leica Microsystems, Wetzlar, Germany). Detailed information on immunostaining for the “no primary antibody” controls is provided in Supplemental Materials and Methods.

Image Analysis

Images were captured at random culture sites for each treatment condition using a fluorescence microscope (Leica DM 2500, Leica Microsystems). Quantification of fluorescent signals in the images was conducted using ImageJ software (version 0.19.0, JASP Team, 2024). Fluorescence intensity was calculated as the number of cells with fluorescent signals divided by the total number of cells with DAPI staining in each image; this was then expressed as a percentage of the VEH ratio.

Statistical Analysis

All results are expressed as mean ± standard error. These were analyzed using OriginPro (version 2024; OriginLab Corporation, Northampton, MA, USA). All data were analyzed using a one-way analysis of variance (ANOVA) with post-hoc Tukey’s test. Statistical significance was set at P < .05.

A comprehensive list of abbreviations is presented in Table 1.

Table 1.

List of Abbreviations.

Abbreviation	Full Name
Akt or PKB	Protein kinase B
AMPK	Adenosine monophosphate-activated protein kinase
APP/PS1	Amyloid precursor protein/presenilin 1
BDNF	Brain-derived neurotrophic factor
CamKII	Calmodulin-dependent protein kinase II
D1R	Dopamine D1 receptor
D2R	Dopamine D2 receptor
D3R	Dopamine D3 receptor
D4R	Dopamine D4 receptor
D5R	Dopamine D5 receptor
DA	Dopamine
DAPI	4′,6-diamidino-2-phenylindole
DARPP-32	Dopamine- and cAMP-regulated phosphoprotein of molecular weight 32 kDa
DAT	Dopamine transporter
ERK	Extracellular regulated kinase
GluN2B	Glutamate receptor subunit epsilon-2
GSK3	Glycogen synthase kinase-3
ICR	Institute of Cancer Research
MAP2	Microtubule-associated protein 2
NPx	Nanoplastics
PBS	Phosphate buffer saline
SYP	Synaptophysin
TH	Tyrosine hydroxylase
ULK1	Unc-51 like autophagy activating kinase 1
VEH	Vehicle
VMAT-2	Vesicular monoamine transporter-2

Results

NPx treatment induced the accumulation of NPx at 3.033 × 10¹⁰ and 3.033 × 10¹¹ particles/mL (F (6.57) = 28.107, P < .001, Tukey’s post-hoc test, P < .001 for VEH vs NPx 3.033 × 10¹⁰ particles/mL, P < .001 for VEH vs NPx 3.033 × 10¹¹ particles/mL; Figures 1a and 2a). However, NPx treatment showed no significant differences in MAP2 (F (6.121) = 1.810, P = .103), TH (F (6.49) = 1.837, P = .111), DAT (F (6.49) = 1.863, P = .106), SYP (F (6.47) = 1.178, P = .334), and DA (F (6.49) = 1.011, P = .429) levels compared with VEH treatment (Figures 1a-c and 2b-f).

Figure 1.

NPx accumulation visualized with fluorescent-NPx and the effect of NPx on the DA system in cerebrocortical neurons. Fluorescent images of cerebrocortical neurons treated with NPx showing DAPI (blue color) and (a) NPx (green color) and MAP2 (red color); (b) TH (green) and the DAT (red); and (c) SYP (green) and DA (red). DA, dopamine; DAPI, 4′,6-diamidino-2-phenylindole; MAP2, microtubule-associated protein 2; NPx, nanoplastics; SYP, synaptophysin; TH, tyrosine hydroxylase; VEH, vehicle.

Figure 2.

The intensity of NPx accumulation and protein expression modulated by NPx treatment. The intensity of fluorescence for (a) NPx, (b) MAP2, (c) TH, (d) DAT, (e) SYP, and (f) DA. A one-way ANOVA with a post-hoc Tukey’s test was used to analyze the fluorescence intensities for significance, with P < .05. ANOVA, analysis of variance; DA, dopamine; DAT, dopamine transporter; MAP2, microtubule-associated protein 2; NPx, nanoplastics; SYP, synaptophysin; TH, tyrosine hydroxylase; VEH, vehicle.

Of the five types of DA receptors, NPx treatment increased the levels of D1R and D2R. D1R levels increased with the two highest doses of NPx compared with VEH treatment (F (6.57) = 9.026, P < .001, Tukey’s post-hoc test, P = .016 for VEH vs NPx 3.033 × 10¹⁰ particles/mL, P < .001 for VEH vs 3.033 × 10¹¹ particles/mL; Figures 3a and 4b). NPx treatment also increased D2R levels compared with VEH treatment (F (6.57) = 5.879, P < .001, Tukey’s post-hoc test, P = .004 for VEH vs NPx 3.033 × 10¹¹ particles/mL; Figures 3a and 4a). However, the levels of D3R (F (6.57) = 1.858, P = .104; Figures 3b and 4c), D4R (F (6.57) = 3.438, P = .006; Figures 3c and 4f), and D5R (F (6.57) = 2.494, P = .033; Figures 3b and 4d) were not significantly altered by NPx treatment according to Tukey’s post-hoc test. Furthermore, the co-expression of D1R–D2R was significantly increased at the highest dose of NPx treatment (F (6.57) = 6.152, P < .001, Tukey’s post-hoc test, P = .004 for VEH vs NPx 3.033 × 10¹¹ particles/mL; Figure 5a and b, Supplemental Fig. S1). Moreover, no fluorescence was detected in the “no primary antibody” controls (Supplemental Fig. S2).

Figure 3.

The effects of NPx on DA receptor expression in cerebrocortical neurons. Fluorescent images of cerebrocortical neurons treated with NPx showing DAPI (blue color) and (a) D2R (green color) and D1R (red color), (b) D3R (green) and D5R (red), and (c) MAP2 (green) and D4R (red). D1R, dopamine D1 receptor; D2R, dopamine D2 receptor; D3R, dopamine D3 receptor; D4R, dopamine D4 receptor; D5R, dopamine D5 receptor; DA, dopamine; DAPI, 4′,6-diamidino-2-phenylindole; MAP2, microtubule-associated protein 2; NPx, nanoplastics; VEH, vehicle.

Figure 4.

The intensity of DA receptor and MAP2 expression modulated by NPx treatment. The intensity of fluorescence for (a) D2R, (b) D1R, (c) D3R, (d) D5R, (e) MAP2, and (f) D4R. A one-way ANOVA with a post-hoc Tukey’s test was used to analyze the fluorescence intensities for significance, with P < .05. ANOVA, analysis of variance; D1R, dopamine D1 receptor; D2R, dopamine D2 receptor; D3R, dopamine D3 receptor; D4R, dopamine D4 receptor; D5R, dopamine D5 receptor; DA, dopamine; MAP2, microtubule-associated protein 2; NPx, nanoplastics; VEH, vehicle.

Figure 5.

The intensity of D1R and D2R co-expression modulated by NPx treatment. (a) Fluorescent images of cerebrocortical neurons treated with NPx showing DAPI (blue color), D2R (green color), D1R (red color), and its merge (yellow color). (b) The intensity of fluorescence for the merge of D1R and D2R. A one-way ANOVA with a post-hoc Tukey’s test was used to analyze the fluorescence intensities for significance, with P < .05. ANOVA, analysis of variance; D1R, dopamine D1 receptor; D2R, dopamine D2 receptor; DAPI, 4′,6-diamidino-2-phenylindole; NPx, nanoplastics; VEH, vehicle.

Discussion

We investigated the effects of NPx on the DA system of cultured cerebrocortical neurons. We found that NPx accumulated in the neurons and increased the levels of D1R, D2R, and their co-expression. These findings indicate that NPx affects the DA systems in neurons.

NPx has been reported to accumulate both in vivo and in vitro. In A549, HepG2, and Caco-2 cells, prolonging treatment times increased the amount of 70, 200, and 500 nm particles that accumulated intracellularly.²¹ In vivo, 20 nm and 220 nm NPx can be detected in various organs, including the intestine, heart, lung, and kidney, up to 48 h after NPx ingestion.²² Moreover, mice treated with 100 nm and 500 nm NPx for 180 days showed reduced hepatic NPx accumulation, attenuated lysosomal function, and autophagic flux after a recovery period of 30 or 50 days.²³ Mice treated with NPx (average size, 531.2 ± 97.83 nm) for 2 months, followed by a withdrawal time of 1 month, induced attenuation of spatial memory impairment in both ICR and APP/PS1 mice.²⁴ These findings indicate that NPx accumulation itself is a critical factor in living organisms. In this study, we found that 100 nm NPx accumulated in cerebrocortical neurons, particularly at high doses. These results indicate that NPx accumulation is an important factor in the DA system; however, whether NPx withdrawal can attenuate alterations in the DA system remains to be elucidated.

Alterations in DA receptor levels were induced only in the high-dose NPx treatment group. In our study, 100 nm NPx were treated at concentrations between 1.896 × 10⁵ particles/mL and 3.033 × 10¹¹ particles/mL, which equates to a range of 0.156 ng/mL to 250 μg/mL. A previous study has reported that 50–200 μg/mL of 100 nm NPx in the mixed neurons induced neuronal apoptosis with intracellular accumulation of NPx.²⁵ Therefore, the NPx doses used in our study are typical doses for studying NPx toxicity. However, these concentrations of NPx may not be appropriate in human or in vivo systems. In particular, humans are estimated to ingest 0–1 mm microparticles at 0.1–5 g/week.²⁶ In addition, a blood concentration of 1.6 μg/mL has been reported in humans for microparticles larger than 700 nm.²⁷ Although the toxicological study of NPx using a cellular system was performed with an overdose compared with the NPx concentrations expected in humans, it may also be useful for predicting NPx effects in living organisms.

In mice, administering 50 and 500 nm NPx for 24 h induced biodistribution over a wide range, from the intestine to the brain. Furthermore, their repeated administration over 28 days resulted in increased accumulation and reactive oxygen species generation in the intestine.²⁸ Moreover, 50 nm NPx administered in mice for 32 weeks increased levels of reactive oxygen species and malondialdehyde and decreased the activity of superoxide dismutase and glutathione peroxide in the intestine.²⁹ In Caco-2 cells, 8 weeks of 50 nm NPx treatment was reported to cause increased oxidative DNA damage with increasing accumulation.³⁰ Recently, 2 weeks of 100 nm NPx administration in mice was reported to induce increased locomotion under L-DOPA treatment.³¹ These results suggest that NPx can accumulate in living organisms and affect neuronal function via the DA system, although the size and dose of NPx, as well as the duration and tissue type treated with NPx, may also affect their accumulation and effect.

NPx treatment specifically increased D1R and D2R levels but not DA synthesis or reuptake. There are five types of DA receptors: D1R, D2R, D3R, D4R, and D5R. D1R induces increased intracellular levels of cAMP by activating adenylate cyclase, whereas D2R causes decreased intracellular levels of cAMP by inhibiting adenylate cyclase.¹¹ In contrast, D1R–D2R heterodimers exhibit different functions from those of the D1R or D2R homodimers. For example, the heterodimers induce intracellular calcium release by activating phospholipase C,³² and this signal affects synaptic plasticity and causes psychiatric disorders. Furthermore, D1R–D2R heterodimers induce calmodulin-dependent protein kinase II (CamKII) activation and modulate brain-derived neurotrophic factor (BDNF) and glutamate receptor subunit epsilon-2 (GluN2B).³² Activated D1R–D2R heterodimers also affect DA- and cAMP-regulated phosphoprotein of molecular weight 32 kDa (DARPP-32)/extracellular regulated kinase (ERK), which are associated with the D1R homodimer and protein kinase B (PKB or Akt)/glycogen synthase kinase-3 (GSK3), which are associated with the D2R homodimer.^33,34 These interactions suggest that D1R–D2R heterodimers affect neural plasticity both individually and in relation to the signaling cascade of D1R or D2R homodimers, thereby causing depression, addiction, anxiety, and schizophrenia.^32-34 In our study, the levels of D1R and D2R, as well as their co-expression, were highest at the highest concentration of NPx. This suggests that the effect of NPx in cerebrocortical neurons is associated with D1R–D2R heterodimers. However, the effects of NPx on the signaling cascades of D1R, D2R, and D1R–D2R heterodimers need further investigation.

Previous studies have reported that NPx administration induces impairment of brain function. In mice, 531.2 ± 97.83 nm NPx decreased motility and spatial memory,²⁴ and 23.03 ± .266 nm NPx increased anxiety and decreased defensive responses, with no changes in motility.³⁵ Moreover, prenatal treatment with 193 nm NPx led to offspring that exhibited depressive and abnormal social behaviors without any alterations in spatial or object memory.³⁶ Notably, DA receptor-associated signaling cascades have been found to be associated with various behaviors, including spatial memory, anxiety, depression, and social ability.^11,32 Therefore, disruptions in the DA system can cause various psychiatric disorders, including Parkinson’s disease, major depression disorder, and schizophrenia.^12,37-39 These results suggest that an altered DA system induced by NPx treatment may be associated with the neuronal dysfunction that causes these psychiatric disorders, although the mechanism through which NPx treatment affects neuronal function by modulating the DA system requires further investigation.

Unlike DA receptor alterations, DA levels showed no changes with NPx treatment. In Caenorhabditis elegans, 100 μg/L of microplastics induced increased levels of glutamate, serotonin, DA, and γ-aminobutyric acid.⁴⁰ In contrast, 1.5 ppm of 70 nm NPx in zebrafish decreased the levels of DA, serotonin, and γ-aminobutyric acid.⁴¹ However, studies on the effects of NPx administration on neurotransmitter synthesis and reuptake in humans and rodents are rare, although NPx have been reported to affect neuronal function.⁸ Therefore, our results suggest that NPx specifically affect DA receptors rather than DA turnover; nonetheless, further investigations are required to elucidate the effects of NPx treatment on the DA receptor signaling cascade.

This study has several limitations. First, although NPx did not induce alterations in DA synthesis or reuptake, DA degradation may have been affected. Exposure to mercury as a pollutant showed a negative correlation with monoamine oxidase in the cerebral cortex of wild river otters.⁴² Further research is required to elucidate the effects of NPx on DA degradation. Second, our study used only 100 nm NPx; however, NPx consist of complexes of various sizes in nature. Exposure to complexes of 50 nm and 500 nm showed greater accumulation than exposures to complexes of 50 nm or 500 nm alone in the organs of mice.²⁸ Therefore, further research is needed to clarify the effect of exposure to complexes of NPx of various sizes. Third, the duration of NPx treatment in this study was only 24 h; however, increasing the NPx treatment duration has been shown to induce an increase in oxidative DNA damage.³⁰ Recently, changes in D1R and DAT levels were reported after only 24 h of Hizikia fusiformis treatment in cerebrocortical neurons, suggesting that 24 h of NPx treatment is sufficient to clarify its effects on the DA system.⁴³ Nonetheless, further studies are needed to elucidate how long-term NPx treatment affects the DA system. Lastly, we only examined changes in DA receptor levels without further assessing their signaling cascade, including intracellular calcium levels. Further studies are required to clarify how NPx affects neuronal function via DA receptors.

In this study, NPx accumulated in the cerebrocortical neurons, resulting in increased levels of D1R, D2R, and their co-expression. These findings indicate that NPx is a potential modulator of the DA system in cerebrocortical neurons and may be associated with DA system-based psychiatric disorders.

Supplemental Material

Supplemental Material - The Effects of Nanoplastics on the Dopamine System of Cerebrocortical Neurons

Supplemental Material for The Effects of Nanoplastics on the Dopamine System of Cerebrocortical Neurons by Na-Hyun Kim and Young-A Lee in International Journal of Toxicology.

Footnotes

Author Contributions

Kim, Na-Hyun contributed to acquisition and analysis and drafted manuscript; Lee, Young-A contributed to conception and design, contributed to analysis and interpretation, drafted manuscript, and critically revised manuscript. Both authors gave final approval and agree to be accountable for all aspects of work ensuring integrity and accuracy.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (Ministry of Science and ICT, MSIT) (NRF-2020R1F1A1048370).

Ethical Statement

ORCID iD

Young-A Lee

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.*

Supplemental Material

Supplemental material for this article is available online.

References

Ali

Katsouli

Marczylo

Gant

Wright

Bernardino de la Serna

. The potential impacts of micro-and-nano plastics on various organ systems in humans. EBioMedicine. 2024;99:104901. doi:10.1016/j.ebiom.2023.104901.

Bermúdez

Swarzenski

. A microplastic size classification scheme aligned with universal plankton survey methods. MethodsX. 2021;8:101516. doi:10.1016/j.mex.2021.101516.

Sharma

Lichtfouse

Robert

. Nanoplastics are potentially more dangerous than microplastics. Environ Chem Lett. 2023;21(4):1933-1936. doi:10.1007/s10311-022-01539-1.

Alqahtani

Saquib

Mohiddin

. Toxicological impact of microplastics and nanoplastics on humans: understanding the mechanistic aspect of the interaction. Front Toxicol. 2023;5:1193386. doi:10.3389/ftox.2023.1193386.

Zhu

Zuo

Qian

. Identification of microplastics in human placenta using laser direct infrared spectroscopy. Sci Total Environ. 2023;856:159060. doi:10.1016/j.scitotenv.2022.159060.

Prüst

Meijer

Westerink

RHS

. The plastic brain: neurotoxicity of micro- and nanoplastics. Part Fibre Toxicol. 2020;17(1):24. doi:10.1186/s12989-020-00358-y.

Zhao

Rehati

Yang

Cai

Guo

. The potential toxicity of microplastics on human health. Sci Total Environ. 2024;912:168946. doi:10.1016/j.scitotenv.2023.168946.

Liu

Yin

Zhu

Liao

Jiang

. Neurotoxicities induced by micro/nanoplastics: a review focusing on the risks of neurological diseases. J Hazard Mater. 2024;469:134054. doi:10.1016/j.jhazmat.2024.134054.

Puig

Rose

Schmidt

Freund

. Dopamine modulation of learning and memory in the prefrontal cortex: insights from studies in primates, rodents, and birds. Front Neural Circ. 2014;8:93. doi:10.3389/fncir.2014.00093.

10.

Speranza

di Porzio

Viggiano

de Donato

Volpicelli

. Dopamine: the neuromodulator of long-term synaptic plasticity, reward and movement control. Cells. 2021;10(4):735. doi:10.3390/cells10040735.

11.

Kawahata

Finkelstein

Fukunaga

. Dopamine D1-D5 receptors in brain nuclei: implications for health and disease. Receptor. 2024;3(2):155-181. doi:10.3390/receptors3020009.

12.

Kesby

Eyles

McGrath

Scott

. Dopamine, psychosis and schizophrenia: the widening gap between basic and clinical neuroscience. Transl Psychiatry. 2018;8(1):30. doi:10.1038/s41398-017-0071-9.

13.

Véronneau-Veilleux

Robaey

Ursino

Nekka

. A mechanistic model of ADHD as resulting from dopamine phasic/tonic imbalance during reinforcement learning. Front Comput Neurosci. 2022;16:849323. doi:10.3389/fncom.2022.849323.

14.

Iarkov

Barreto

Grizzell

Echeverria

. Strategies for the treatment of Parkinson’s disease: beyond dopamine. Front Aging Neurosci. 2020;12:4. doi:10.3389/fnagi.2020.00004.

15.

Grønnestad

Johanson

Müller

MHB

, et al. Effects of an environmentally relevant PFAS mixture on dopamine and steroid hormone levels in exposed mice. Toxicol Appl Pharmacol. 2021;428:115670. doi:10.1016/j.taap.2021.115670.

16.

Chang

Kueon

Kim

. Influence of lead on repetitive behavior and dopamine metabolism in a mouse model of iron overload. Toxicol Res. 2014;30(4):267-276. doi:10.5487/tr.2014.30.4.267.

17.

Choi

Lee

Kim

Bae

. Particulate matter exacerbates the death of dopaminergic neurons in Parkinson’s disease through an inflammatory response. Int J Mol Sci. 2022;23(12):6487. doi:10.3390/ijms23126487.

18.

Chen

Yin

Jia

, et al. Enhanced uptake of BPA in the presence of nanoplastics can lead to neurotoxic effects in adult zebrafish. Sci Total Environ. 2017;609:1312-1321. doi:10.1016/j.scitotenv.2017.07.144.

19.

Huang

Liang

, et al. Polystyrene nanoplastic exposure induces excessive mitophagy by activating AMPK/ULK1 pathway in differentiated SH-SY5Y cells and dopaminergic neurons in vivo. Part Fibre Toxicol. 2023;20(1):44. doi:10.1186/s12989-023-00556-4.

20.

Han

Baek

Kim

, et al. Generation of embryonic stem cells derived from the inner cell mass of blastocysts of outbred ICR mice. Anim Cell Syst. 2020;24(2):91-98. doi:10.1080/19768354.2020.1752306.

21.

Zhang

H-J

Zhou

H-R

Pan

, et al. Accumulation of nanoplastics in human cells as visualized and quantified by hyperspectral imaging with enhanced dark-field microscopy. Environ Int. 2023;179:108134. doi:10.1016/j.envint.2023.108134.

22.

Keinänen

Dayts

Rodriguez

, et al. Harnessing PET to track micro- and nanoplastics in vivo. Sci Rep. 2021;11(1):11463. doi:10.1038/s41598-021-90929-6.

23.

Y-Y

Ren

H-Y

, et al. The size-dependence and reversibility of polystyrene nanoplastics-induced lipid accumulation in mice: possible roles of lysosomes. Environ Int. 2024;185:108532. doi:10.1016/j.envint.2024.108532.

24.

Yang

Dai

Cheng

, et al. Oral feeding of nanoplastics affects brain function of mice by inducing macrophage IL-1 signal in the intestine. Cell Rep. 2023;42(4):112346. doi:10.1016/j.celrep.2023.112346.

25.

Jung

Han

Park

Bae

Choi

Ryu

. Neurotoxic potential of polystyrene nanoplastics in primary cells originating from mouse brain. Neurotoxicology. 2020;81:189-196. doi:10.1016/j.neuro.2020.10.008.

26.

Senathirajah

Attwood

Bhagwat

Carbery

Wilson

Palanisami

. Estimation of the mass of microplastics ingested - a pivotal first step towards human health risk assessment. J Hazard Mater. 2021;404(Pt B):124004. doi:10.1016/j.jhazmat.2020.124004.

27.

Leslie

van Velzen

MJM

Brandsma

Vethaak

Garcia-Vallejo

Lamoree

. Discovery and quantification of plastic particle pollution in human blood. Environ Int. 2022;163:107199. doi:10.1016/j.envint.2022.107199.

28.

Liang

Zhong

Huang

, et al. Underestimated health risks: polystyrene micro- and nanoplastics jointly induce intestinal barrier dysfunction by ROS-mediated epithelial cell apoptosis. Part Fibre Toxicol. 2021;18(1):20. doi:10.1186/s12989-021-00414-1.

29.

, et al. Chronic exposure to polystyrene nanoplastics induces intestinal mechanical and immune barrier dysfunction in mice. Ecotoxicol Environ Saf. 2024;269:115749. doi:10.1016/j.ecoenv.2023.115749.

30.

Domenech

de Britto

Velázquez

, et al. Long-term effects of polystyrene nanoplastics in human intestinal Caco-2 cells. Biomolecules. 2021;11(10):1442. doi:10.3390/biom11101442.

31.

Kim

Choo

Lee

. Effect of nanoplastic intake on the dopamine system during the development of male mice. Neuroscience. 2024;555:11-22. doi:10.1016/j.neuroscience.2024.07.018.

32.

Zhao

Cheng

Piao

Cui

. Dopamine receptors: is it possible to become a therapeutic target for depression? Front Pharmacol. 2022;13:947785. doi:10.3389/fphar.2022.947785.

33.

Hasbi

Perreault

Shen

MYF

, et al. Activation of dopamine D1-D2 receptor complex attenuates cocaine reward and reinstatement of cocaine-seeking through inhibition of DARPP-32, ERK, and ΔFosB. Front Pharmacol. 2018;8:924. doi:10.3389/fphar.2017.00924.

34.

Perreault

Hasbi

O'Dowd

George

. Heteromeric dopamine receptor signaling complexes: emerging neurobiology and disease relevance. Neuropsychopharmacology. 2014;39(1):156-168. doi:10.1038/npp.2013.148.

35.

Guimarães

ATB

Freitas

ÍN

Mubarak

, et al. Exposure to polystyrene nanoplastics induces an anxiolytic-like effect, changes in antipredator defensive response, and DNA damage in Swiss mice. J Hazard Mater. 2023;442:130004. doi:10.1016/j.jhazmat.2022.130004.

36.

Shin

Lee

Moon

, et al. Exposure to polystyrene particles causes anxiety-depression-like behavior and abnormal social behavior in mice. J Hazard Mater. 2023;454:131465. doi:10.1016/j.jhazmat.2023.131465.

37.

Thurm

Schuck

Fauser

, et al. Dopamine modulation of spatial navigation memory in Parkinson’s disease. Neurobiol Aging. 2016;38:93-103. doi:10.1016/j.neurobiolaging.2015.10.019.

38.

Beyer

DKE

Mattukat

Freund

. Prefrontal dopamine D1 receptor manipulation influences anxiety behavior and induces neuroinflammation within the hippocampus. Int J Bipolar Disord. 2021;9(1):9. doi:10.1186/s40345-020-00212-2.

39.

Mizuno

Ashok

Bhat

Jauhar

Howes

. Dopamine in major depressive disorder: a systematic review and meta-analysis of in vivo imaging studies. J Psychopharmacol. 2023;37(11):1058-1069. doi:10.1177/02698811231200881.

40.

Xie

Yang

, et al. Carboxyl-modified polystyrene microplastics induces neurotoxicity by affecting dopamine, glutamate, serotonin, and GABA neurotransmission in Caenorhabditis elegans. J Hazard Mater. 2023;445:130543. doi:10.1016/j.jhazmat.2022.130543.

41.

Sarasamma

Audira

Siregar

, et al. Nanoplastics cause neurobehavioral impairments, reproductive and oxidative damages, and biomarker responses in zebrafish: throwing up alarms of wide spread health risk of exposure. Int J Mol Sci. 2020;21(4):1410. doi:10.3390/ijms21041410.

42.

Basu

Scheuhammer

Evans

O'Brien

Chan

. Cholinesterase and monoamine oxidase activity in relation to mercury levels in the cerebral cortex of wild river otters. Hum Exp Toxicol. 2007;26(3):213-220. doi:10.1177/0960327107070570.

43.

Jung

Kim

Choi

Goto

Lee

. Dopamine and serotonin alterations by Hizikia fusiformis extracts under in vitro cortical primary neuronal cell cultures. Nutr Res Prac. 2023;17(3):408-420. doi:10.4162/nrp.2023.17.3.408.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.38 MB